Under the Paperwork Reduction Act of 1995.	U.S. P no persons are required to respond to a coll Application Number	atent and Trademark Office U	P/TO/SB/21 (09-04) hrough 07/31/2006. OMB 0651-0031 S. DEPARTMENT OF COMMERCE displays a valid OMB control number.
TRANSMITTAL FORM	Filing Date First Named Inventor Art Unit	November 10, 2000 M. Rigdon Lentz 1647	
(to be used for all correspondence after initial Total Number of Pages in This Submission	Examiner Name Attorney Docket Number	Lorraine Spector LEN 102	
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocatio Change of Correspondence A Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CE	Appea of App Appea (Appea (Appea Appea) Appea	Enclosure(s) (please Identify
Firm Name Pabst Patent Gro	TURE OF APPLICANT, ATTO	RNEY, OR AGENT	
Printed name Tiffany B. Salmon Date February 11, 200		Reg. No. 55,589	
I hereby certify that this correspondence is to sufficient postage as first class mail in an ere the date shown below: Signature	ERTIFICATE OF TRANSMISS peing facsimile transmitted to the USPT evelope addressed to: Commissioner for	O or deposited with the Ur	nited States Postal Service with Alexandria, VA 22313-1450 on
Typed or printed name Ronna Bern	nan Suna	Date	February //, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number Complete if Known Effective on 12/08/2004 Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). 09/709,045 **Application Number** TRANSMIT Filing Date November 10, 2000 For FY 2005 M. Rigdon Lentz First Named Inventor L. Spector **Examiner Name** Applicant claims small entity status. See 37 CFR 1.27 1647 Art Unit RADEMA (\$) 180.00TOTAL AMOUNT OF PAYMENT **LEN 102** Attorney Docket No METHOD OF PAYMENT (check all that apply) Check Credit Card Money Order None Other (please identify): ✓ Deposit Account Deposit Account Number: 50-3129 Deposit Account Name: Pabst Patent Group LLP For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) ✓ Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee Charge any additional fee(s) or underpayments of fee(s) Credit any overpayments under 37 CFR 1.16 and 1.17 WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. **FEE CALCULATION** 1. BASIC FILING, SEARCH, AND EXAMINATION FEES **FILING FEES** SEARCH FEES EXAMINATION FEES **Small Entity Small Entity Small Entity** Fees Paid (\$) **Application Type** Fee (\$) Fee (\$) Fee (\$) Fee (\$) Fee (\$) Fee (\$) 300 200 500 Utility 150 250 100 200 100 100 50 130 65 Design 200 160 80 Plant 300 100 150 300 500 600 300 Reissue 150 250 200 0 0 0 Provisional 100 0 2. EXCESS CLAIM FEES **Small Entity** Fee (\$) Fee (\$) **Fee Description** Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent 50 25 Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent 200 100 180 Multiple dependent claims Fee Paid (\$) **Multiple Dependent Claims Extra Claims Total Claims** Fee (\$) Fee Paid (\$) =0<u>.00</u> <u>14</u> - 20 or HP = 0 Fee (\$) HP = highest number of total claims paid for, if greater than 20 Fee Paid (\$) Fee (\$) Indep. Claims **Extra Claims** 0.00 HP = highest number of independent claims paid for, if greater than 3 3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Number of each additional 50 or fraction thereof Fee Paid (\$) **Total Sheets** (round up to a whole number) x - 100 = Fees Paid (\$) 4. OTHER FEE(S) Non-English Specification, \$130 fee (no small entity discount)

SUBMITTED BY				
Signature	-03 dic	Registration No. (Attorney/Agent)	55,589	Telephone (404) 879-2153
Name (Print/Type)	Tiffany B. Salmon			Date February 11, 2005

Other: Information Disclosure Statement

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

180.00



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

M. Rigdon Lentz

Serial No.:

09/709,045

Art Unit:

1647

Filed:

November 10, 2000

Examiner:

Lorraine Spector

For:

METHOD AND SYSTEM TO REMOVE CYTOKINE INHIBITOR IN PATIENTS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits a Supplemental Information Disclosure Statement, including one (1) page of Form PTO-1449, and copies of the five (5) documents cited therein.

The Commissioner is hereby authorized to charge \$180.00 representing the fee required under 37 C.F.R. §1.17(p) for an Information Disclosure Statement filed after a first Office Action on the merits under 37 C.F.R. §1.97(c). It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-3129.

U.S. Patents

Number Issue Date Patentee Class/Subclass 5,932,704 08-03-1999 Jubinsky 530/388.22

02/16/2005 BABRAHA1 00000007 503129 09709045

01 FC:1806

180.00 DA

45054471v1

U.S.S.N.: 09/709,045

Filed: November 10, 2000

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

Foreign Documents

Number	Publication Date	<u>Patentee</u>	Country
0 184 040	11-06-1986	Anisa Medical Inc.	EP
02045064	02-15-1990	Ube Industries	JP
WO 96/16666	06-06-1996	Sanitaria Scaligera S.P.A.	PCT

Publications

GERAIN, et al., "Systemic release of soluble TNF receptors after high-dose TNG in isolated limb perfusion" *Cytokine* 9(12):1034-1042 (1997).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

Tiffany B. Salmon

Reg. No. 55,589

Dated: February 11, 2005

PABST PATENT GROUP LLP 400 Colony Square, Suite 1200 1201 Peachtree Street Atlanta, Georgia 30361 (404) 879-2153 (Telephone) (404) 879-2160 (Fax)

	Substitut	e for form 1449	A/PTO	Complete if Known		
	1 P E 3005	STATEME	TION DISCLOSURE NT BY APPLICANT any sheets as necessary)	Application Number	09/709,045	
B				Filing Date	November 10, 2000	
THE PARTY.	8			First Named Inventor	M. Rigdon Lentz	
₹.	RADEMARK DE			Group Art Unit	1647	
`	MADER			Examiner Name	Lorraine Spector	
	Sheet 1	of	2	Attorney Docket Number	LEN 102	

		U.S. PATENT DOCUM	MENTS	
Examiner Initials*	US Patent Document Number Kind Code 2	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
ļ	(if known)			
	5,932,704	Jubinsky	08-03-1999	
_				
	 <u> </u>			

				F	OREIGN PATENT DOCUMENT	rs				
Examiner Initials*	Cite No.1					nent		Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
		Office.3	Number ⁴	Kind Code⁵ (if known)]		- ''			
		EP	0 184 040	_	Anisa Medical Inc.	06-11-1986				
		JP	02045064		Ube Industries	02-15-1990				
		PCT	WO 96/16666	ļ	Santaria Scaligera S.P.A.	06-06-1996				
		 								
i	1	1		1				L		

Examiner's	Date Consider	ed
Signature		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

The PTO did not receive the following listed Item(s) 19-0-20-4-57-6-4

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-96	_
0/31/99. OMB 0651-0031	+
T. (E.) T. O.C. O.O. W. (C.D.O.E.	•

	Substitute for form 1449A/PTO			Complete if Known		
6	Cias S	TATEME	TION DISCLOSURE NT BY APPLICANT any sheets as necessary)	Application Number	09/709,045	
	1 1 2005 3	•••	•	Filing Date	November 10, 2000	
ERTELY.	₽ .₩			First Named Inventor	M. Rigdon Lentz	
B	🙀			Group Art Unit	1647	
VZ	Sheet 2			Examiner Name	Lorraine Spector	
7	Sheet 2	of	2	Attorney Docket Number	LEN 102	

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		GERAIN, et al., "Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion" <i>Cytokine</i> 9(12):1034-1042 (1997).	
	٠		
			-
[Fuencia aria		Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Signature

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.